Spread and Release of Measles in the Airways
Spread and Release of Measles in the Airways
批准号:
10408155
负责人:
PATRICK L SINN
金额:
$49.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-01 至 2024-06-30
关键词:
AddressAlveolarAnimal ModelAnimalsAntiviral ResponseApicalApoptosisAutophagocytosisBenignBiological ModelsCell DeathCell LineCell ProliferationCell membraneCell modelCell surfaceCellsChildChildhoodClinicalContractsCoughingDataDiseaseEnvironmentEpithelialEpithelial CellsEuropeEventExanthemaF-ActinFrequenciesGenesGiant CellsGoalsGrowthHerd ImmunityHourHumanInfectionInnate Immune ResponseInterferonsIrrigationKnowledgeLabelLaboratoriesLasersLeadLinkLymphatic SystemMacacaMacaca mulattaMapsMeaslesMeasles virusMediatingMicroscopicModelingModificationMonitorMovementPathologyPathway interactionsPersonsPhysiologicalProcessProteinsReportingResearchRoleRuptureSentinelSeriesSneezingSurfaceTestingTimeVaccinationViral PathogenesisViremiaVirionVirusVirus DiseasesWorkairway epitheliumbasebasolateral membranecell immortalizationcontagiondeep sequencinggenetic approachhuman modelimprovedin vitro Modelin vivoinhibitorinnovationinsightnectinnonhuman primatepathogenpathogenic viruspreferenceprogramsreceptorrespiratory virusresponsetransmission processtreadmillvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY:
Humans are the only natural reservoir for the extremely contagious measles virus (MeV). Thus, a critical
challenge for MeV study is identification of representative human model systems. For decades, MeV was
thought to enter the human host through the apical surface of airway cells, a misconception based on studies
in immortalized cell lines. Well-differentiated primary cultures of airways epithelial cells from human donors
(HAE) provide a more physiological relevant model of human airways. Using HAE, we found that MeV
exclusively enters the basolateral membrane. This observation lead to a completely new paradigm for how
MeV enters the human host. In addition to basolateral entry, we observed that MeV infection of HAE results in
the formation of infectious centers that retain intact plasma membranes and are substantially different than
the syncytia observed in immortalized cells. Infectious centers differ from syncytia in two important ways: 1)
infectious centers stop growing 3-4 days post-infection and 2) infectious centers disappear after ~10 days
leaving the cell layer intact. Why infectious centers stop growing and how they disappear in HAE remain a
mystery and is the focus of this application. We hypothesize that infectious center formation in the respiratory
epithelium is a vital step in the final amplification process before release to the next host. In Aim 1, we define
the innate immune response pathways in the airways. We quantify 14 antiviral sentinel genes at 12 timepoints
ranging from 6 hours to 2 weeks. In addition, laser capture of infectious centers is used to isolate infected cells
from uninfected cells within an epithelial sheet and deep sequencing is used to map the cellular response to
MeV. In Aim 2, we address how MeV is released from HAE. Preliminary data suggest that infectious centers
are shed, intact, from the HAE (rather than rupturing). The timecourse and frequency of shedding will be
defined. The roles of cell proliferation and cell death pathways will be probed by cell labeling to discern how
large infectious centers can be released yet the epithelial integrity is maintained. MeV mediated cytoskeletal
modifications are likely to be mechanistically involved in infectious center release, which we test using
inhibitors of F-actin treadmilling. In Aim 3, we hypothesize that shed infectious centers are physiologically
relevant vectors for MeV delivery. We will deliver cell-associated and cell-free MeV to the airways of rhesus
macaques and quantify the time-course of infection. This aim has the potential to reshape a fundamental
dogma of how MeV is spread host-to-host. In summary, these studies use an appropriate model system to
study MeV entry, spread, and luminal release. Our research will elucidate mechanisms by which the most
contagious human respiratory virus undergoes its final amplification step before release to its next host.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Extracellular Vesicle-Mediated siRNA Delivery, Protein Delivery, and CFTR Complementation in Well-Differentiated Human Airway Epithelial Cells.
细胞外囊泡介导的 siRNA 递送、蛋白质递送和分化良好的人气道上皮细胞中的 CFTR 互补。
DOI:
10.3390/genes11040351
发表时间:
2020
期刊:
Genes
影响因子:
3.5
作者:
[Singh,BrajeshK, Cooney,AshleyL, Krishnamurthy,Sateesh, Sinn,PatrickL]
通讯作者:
Sinn,PatrickL
Measles Virus Ribonucleoprotein Complexes Rapidly Spread across Well-Differentiated Primary Human Airway Epithelial Cells along F-Actin Rings.
麻疹病毒核糖核蛋白复合物沿着 F-肌动蛋白环快速扩散到分化良好的原代人气道上皮细胞中。
DOI:
10.1128/mbio.02434-19
发表时间:
2019
期刊:
mBio
影响因子:
6.4
作者:
[Singh,BrajeshK, Pfaller,ChristianK, Cattaneo,Roberto, Sinn,PatrickL]
通讯作者:
Sinn,PatrickL
Spread and Release of Measles in the Airways
-
批准号:10190793
-
项目类别:
-
资助金额:$52.08万
-
财政年份:2018
-
负责人:PATRICK L SINN
-
依托单位:
Life-long phenotypic correction of CF airways
-
批准号:10653542
-
项目类别:
-
资助金额:$76.86万
-
财政年份:2017
-
负责人:PATRICK L SINN
-
依托单位:
A Hybrid Viral/Nonviral Vector for CFTR Delivery to CF Pig Airways
-
批准号:9923461
-
项目类别:
-
资助金额:$57.52万
-
财政年份:2017
-
负责人:PATRICK L SINN
-
依托单位:
Targeted integration of a DNA transposon-based nonviral vector
-
批准号:8237293
-
项目类别:
-
资助金额:$48.21万
-
财政年份:2012
-
负责人:PATRICK L SINN
-
依托单位:
Targeted integration of a DNA transposon-based nonviral vector
-
批准号:8598929
-
项目类别:
-
资助金额:$33.3万
-
财政年份:2012
-
负责人:PATRICK L SINN
-
依托单位:
Targeted integration of a DNA transposon-based nonviral vector
-
批准号:8988595
-
项目类别:
-
资助金额:$33.98万
-
财政年份:2012
-
负责人:PATRICK L SINN
-
依托单位:
Targeted integration of a DNA transposon-based nonviral vector
-
批准号:8403682
-
项目类别:
-
资助金额:$45.9万
-
财政年份:2012
-
负责人:PATRICK L SINN
-
依托单位:
Targeted Integration of a Lentiviral Vector
-
批准号:7021573
-
项目类别:
-
资助金额:$11.3万
-
财政年份:2006
-
负责人:PATRICK L SINN
-
依托单位:
Targeted Integration of a Lentiviral Vector
-
批准号:7170056
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2006
-
负责人:PATRICK L SINN
-
依托单位:
Targeted Integration of a Lentiviral Vector
-
批准号:7337315
-
项目类别:
-
资助金额:$11.97万
-
财政年份:2006
-
负责人:PATRICK L SINN
-
依托单位:
Pseudotyping FIV to Target Human Airway Epithelia
-
批准号:6555856
-
项目类别:
-
资助金额:$4.62万
-
财政年份:2002
-
负责人:PATRICK L SINN
-
依托单位:
Pseudotyping FIV to Target Human Airway Epithelia
-
批准号:6340380
-
项目类别:
-
资助金额:$4.02万
-
财政年份:2001
-
负责人:PATRICK L SINN
-
依托单位:
Viral Vector
-
批准号:10395538
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2000
-
负责人:PATRICK L SINN
-
依托单位:
Viral Vector
-
批准号:10600158
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2000
-
负责人:PATRICK L SINN
-
依托单位:
Vector Core-Core 2
-
批准号:10225749
-
项目类别:
-
资助金额:$15.67万
-
财政年份:1998
-
负责人:PATRICK L SINN
-
依托单位:
Vector Core-Core 2
-
批准号:10436227
-
项目类别:
-
资助金额:$15.67万
-
财政年份:1998
-
负责人:PATRICK L SINN
-
依托单位:
Vector Core-Core 2
-
批准号:10617353
-
项目类别:
-
资助金额:$15.67万
-
财政年份:1998
-
负责人:PATRICK L SINN
-
依托单位:
Core B: Gene Transfer Vector Core
-
批准号:8935414
-
项目类别:
-
资助金额:$16.61万
-
财政年份:--
-
负责人:PATRICK L SINN
-
依托单位:
Cluster A: 2 Viral Vector Core
-
批准号:9914240
-
项目类别:
-
资助金额:$6.78万
-
财政年份:--
-
负责人:PATRICK L SINN
-
依托单位:
Cluster A: 2 Viral Vector Core
-
批准号:9252404
-
项目类别:
-
资助金额:$5.81万
-
财政年份:--
-
负责人:PATRICK L SINN
-
依托单位:
海外基金